A Phase 1, Open Label, Dose Escalation, Dose Expansion, Multicenter Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of Oral AUR108 in Patients With Relapsed Advanced Lymphomas(ASHA-1)
Latest Information Update: 06 Feb 2024
At a glance
- Drugs AUR 108 (Primary)
- Indications Hodgkin's disease; Lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions; First in man; Pharmacokinetics
- Acronyms ASHA-1
- Sponsors Aurigene Oncology
Most Recent Events
- 29 Jan 2024 Status changed from not yet recruiting to recruiting.
- 11 Aug 2023 New trial record